A sphingosine-1-phosphate receptor 1 (S1P
1) antagonist is expected to be an anti-angiogenic compound; however, there are few reports that demonstrated that a S1P
1 inhibitor improved the disease state in an angiogenic animal model. Since we determined that a prototype S1P
1 antagonist was an
in vivo angiogenesis inhibitor, we developed the derivatives to acquire more effective compounds. In this report, we show the S1P
1 antagonistic activity of some representatives, especially compound 5 {sodium 4-[(4-butoxyphenyl)thio]-2′-[{4-[(heptylthio)methyl]-2-hydroxyphenyl}(hydroxy)methyl]biphenyl-3-sulfonate}. The IC
50 values calculated from an intracellular cyclic AMP measurement assay and a [
33P]sphingosine-1-phosphate (Sph-1-P)/S1P
1 binding assay were 38 and 200 n
M, respectively. A subtype specificity test for the other Sph-1-P receptors showed that compound 5 was the S1P
1-directional antagonist. It also inhibited the proliferation, migration, and tube formation of human umbilical vein endothelial cells stimulated by Sph-1-P with the IC
50 values of 18, 650, and 230 n
M, respectively. A cytotoxicity assay concurrently performed with a tube formation assay supported the hypothesis that these biological effects were not due to its cytotoxicity. Furthermore, administration (10 mg/kg, intravenously) to anesthetized Sprague-Dawley rats inhibited Sph-1-P-induced hypotension by 100—90% for 30 min. This is presumably through the inhibition of Sph-1-P-induced vasorelaxation, mainly by the blocking of S1P
1 and/or S1P
3. Taken together, these results show that compound 5 is an inhibitor of
in vitro and
in vivo Sph-1-P signaling, and that it will be useful to elucidate the
in vivo effect of Sph-1-P on vascular endothelial cells.
View full abstract